No treatment group Statins-treatment group p-value
Number 121 59  
Men (%) 73.6 57.6 0.04
Age (years) 60.9 ± 11.4 67.0 ± 9.9 <0.0001
Duration of diabetes (years) 12.7 ± 9.2 16.6 ± 8.8 0.007
Body Mass Index (kg/m2) 25.0 ± 4.9 26.7 ± 4.0 0.029
Waist circumference (cm) 89.1 ± 10.8 93.0 ± 9.8 0.019
Systolic Blood Pressure (mmHg) 133.6 ± 12.2 135.2 ± 15.8 N.S
Diastolic Blood Pressure (mmHg) 74.9 ± 10.0 71.9 ± 12.5 N.S
Total cholesterol (mg/dL) 221.2 ± 32.9 204.8 ± 28.9 0.001
Triglycerides (mg/dL) 136.0 ± 152.9 166.3 ± 145.3 N.S
HDL cholesterol (mg/dL) 55.7 ± 14.9 54.6 ± 13.3 N.S
LDL cholesterol (mg/dL) 137.2 ± 26.6 115.9 ± 22.9 <0.001
RLP cholesterol (mg/dL) 6.7 ± 16.4 7.0 ± 9.2 N.S
Cholesterol absorption marker/total cholesterol (μg/mg*103) 27.4 ± 9.3 33.5 ± 18.3 <0.05
Cholesterol synthesis maker/total cholesterol (μg/mg*103) 9.1 ± 5.1 5.8 ± 3.5 <0.001
A1C (%) 7.4 ± 1.0 7.6 ± 1.1 N.S
Fasting blood glucose (mg/dL) 138.6 ± 43.1 139.1 ± 46.3 N.S
C-Peptide Reactivity (ng/mL) 1.7 ± 1.0 2.1 ± 1.7 N.S
Concomitant drugs (%)      
Sulfonylurea drugs 40.5 47.5 N.S
α-glucosidase inhibitors 24.0 32.2 N.S
Biguanides/Thiazolidinediones 31.4 49.2 0.023
Insulin 33.1 52.5 0.015
Antihypertensive drugs 38.0 76.3 <0.001
Antiplatelet agents 17.6 36.2 0.008
Risk factors (%)      
Smoker 19.0 15.3 N.S
Family history of coronary artery disease 3.3 5.1 N.S
History of coronary artery disease 4.2 18.6 0.004
History of stroke 7.5 5.1 N.S
History of peripheral artery disease 0.8 1.7 N.S
C-peptide reactivity (reference value): 1.2 to 2.0 ng/mL. Data are expressed as mean ± SD. HDL, high-density lipoprotein; LDL, low-density lipoprotein; RLP, remnant-like particle; A1C, hemoglobin A1C.
Table 1: Clinical data of study patients.